Clinical Trial Update: Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

Duloxetine is being studied in Phase 2/Phase 3 trials to prevent oxaliplatin-induced peripheral neuropathy in patients with stage II-III colorectal cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Duloxetine (DULOXETINE)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8 | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING